LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
To determine whether you have CYP2C9 and/or VKORC1 genetic variations and are likely to need lower, or less commonly, higher than average doses of the "blood-thinning" drug (anticoagulant) warfarin; however, not everyone who is prescribed warfarin will have this test done. At present, there is no consensus on the usefulness of this test and it is not yet widely accepted.
A healthcare practitioner might order this test prior to prescribing warfarin for you or may sometimes order it when you are being treated with warfarin and have had bleeding or clotting episodes or dosing difficulties
A blood sample drawn from a vein, a swab rubbed on the inside of your check (buccal swab), or you spit saliva into a clean container
Warfarin (Coumadin®) is a "blood-thinner" (anticoagulant), a drug that is commonly prescribed to help prevent inappropriate blood clotting (thrombosis and thromboembolism) in individuals at risk. This includes people who have had a blood clot or who have an excessive clotting disorder, atrial fibrillation, an artificial heart valve, or have undergone orthopedic surgery.
Warfarin sensitivity testing helps determine if you may be more sensitive (i.e., require lower doses) to treatment with warfarin because of your genetic makeup. This test primarily detects common genetic variations in two genes, CYP2C9 and VKORC1. A healthcare practitioner may sometimes order this test to help select appropriate doses of warfarin and/or to achieve appropriate dose levels more quickly.
Warfarin can be a challenging drug to administer and monitor because its levels can be affected by many different factors and it has a narrow window in which it is effective. If you are given too little drug, you may be at risk of forming a blood clot; if given too much drug, you may be at risk of moderate to severe bleeding episodes. The range between too much drug and too little drug is small and it varies significantly from person to person.
Historically, healthcare practitioners have given warfarin doses based upon age, weight, and sex, and then have monitored and adjusted dosages using frequent PT/INR (prothrombin time/international normalized ratio) tests to determine the medication's anticoagulant ("blood-thinning") effect. Healthcare practitioners then use periodic PT/INR tests to ensure that a stable dose with sufficient anticoagulation has been achieved. Although this dosing strategy is still commonly used, it can take as long as several weeks.
Genetic testing for warfarin sensitivity may help to shorten the time it takes for you to reach a stable dose; that is, to achieve adequate "blood-thinning" without bleeding episodes. Most often, it is determined that people are more sensitive to warfarin and may need smaller doses; however, there are some people who are less sensitive and may need larger doses. The reason for the relative sensitivity can be, at least in part, due to the individual's genetic makeup and may involve two genes:
You inherit one copy of each of your genes from your mother and one copy of each of your genes from your father. Thus, each of the CYP2C9 and VKORC1 genes is present in your body as two inherited gene copies (alleles). You could have both copies of a gene without any variants (wild-type, normal); one copy without variants and one copy with a variant (heterozygous); both copies with the same variant (homozygous); and both copies with different variants ("compound heterozygous"). The combination of CYP2C9 and VKORC1 gene copies that you have can determine the overall effect of warfarin and how rapidly it is metabolized and cleared from your body.
Warfarin sensitivity (or warfarin genotype) testing determines whether CYP2C9 and VKORC1 gene variants are present. Careful interpretation of the results can help the healthcare practitioner decide the appropriate doses of warfarin for your treatment.
Warfarin sensitivity testing (genotyping) may be used to help determine your likely sensitivity to warfarin and to help select appropriate doses. Warfarin genotyping primarily identifies variations in the VKORC1 gene and the CYP2C9 gene. (See "What is being tested?" for more details on these genes.)
CYP2C9 and VKORC1 genetic testing is not widely used at this time. Although studies have shown that these genes contribute to a person's sensitivity to warfarin and can account for a significant percentage of the person-to-person variation in warfarin doses, there is not a consensus on the need for the testing yet.
Warfarin sensitivity testing may be ordered prior to you taking warfarin for the first time, but it may also be ordered when you have had difficulties with achieving a stable anticoagulant ("blood-thinning") effect or have experienced either excessive blood clotting or bleeding while taking warfarin.
Warfarin sensitivity testing will identify the CYP2C9 and VKORC1 genetic variants (i.e., genotype) present. Laboratories most commonly look for the CYP2C9 variant alleles *2 and *3.The results must be interpreted carefully to help determine if you are likely to need a relatively lower dose of warfarin. These results are often interpreted by a specialist. Some laboratories also test for other genes that may be involved in warfarin sensitivity and dose optimization (e.g., CYP4F2). The laboratory should provide information about any additional genes included in a test.
If you have one or more variant CYP2C9 or VKORC1 gene copies, you are more likely to need a lower dose of warfarin. The amount needed will depend on the number and type of genetic variants present but will also greatly depend upon other factors, including your health, age, sex, diet, and other medications.
This test detects only the most common genetic variants in CYP2C9 and VKORC1. You may have a rare variant, resulting in a negative test result, but may still be more sensitive or resistant to warfarin.
Some major health organizations support warfarin sensitivity testing, while others would like to see more data showing that the use of the testing actually has an impact on the health of the patient, such as a decrease in the number of clotting or bleeding events experienced by those on warfarin. Currently, there are studies underway that may provide additional data on health outcomes in the next few years, and that is likely to help determine the clinical usefulness of testing.
The U.S. Food and Drug Administration (FDA) has created changes to the warfarin label to provide information about the usefulness of CYP2C9 and VKORC1 genetic testing and to provide guidance on warfarin doses based upon testing results.
Many drugs interact with warfarin and can slow the metabolism of warfarin. Make sure all of your healthcare providers are aware of all the medications you are taking.
Yes. Regardless of your genetic makeup, your response to warfarin therapy will still need to be monitored with regular PT/INR tests. This is because your individual degree of anticoagulation ("blood-thinning") can be affected by other factors such as diet, age, weight, other medications and state of health, which can change over time.
No, it requires specialized equipment to perform and expertise to interpret. It is not offered by every laboratory and may need to be sent to a laboratory outside of your hospital (i.e., reference laboratory).
No. This test determines information about the genes you have inherited. This information does not change so you will only need to be tested once.
Yes, and you should always tell them that you are taking warfarin. The use of warfarin and your sensitivity to warfarin is important information for the medical professionals (including dentists) that you see. It can have an effect on your treatment options. CYP2C9 is involved in metabolism of many other drugs.
This is something to discuss with your healthcare provider and family. It is not generally indicated unless a family member is also going to be taking warfarin, but having a family member who has warfarin sensitivity is important information to keep in mind and to share with your healthcare practitioner.
Sources Used in Current Review
(2018 September, Reviewed). Warfarin sensitivity. Genetics Home Reference. Available online at https://ghr.nlm.nih.gov/condition/warfarin-sensitivity. Accessed August 2020.
Farzamikia, N. et. al. (2018). Pharmacogenetics-based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms. Medscape Lab Med. 2018;49(1):25-34. Available online at https://www.medscape.com/viewarticle/890709. Accessed August 2020.
(© 1995–2020). Warfarin Response Genotype, Varies. Mayo Clinic Laboratories. Available online at https://www.mayocliniclabs.com/test-catalog/Overview/97401. Accessed August 2020.
(© 2020). Warfarin Sensitivity (CYP2C8, CYP2C9, CYP4F2, VKORC1) Genotyping. ARUP Consult Test Fact Sheet. Available online at https://arupconsult.com/ati/warfarin-sensitivity-genotyping. Accessed August 2020.
(2018 September, Reviewed). CYP2C9 gene. Genetics Home Reference. Available online at https://ghr.nlm.nih.gov/gene/CYP2C9. Accessed August 2020.
Johnson, J. et. al. (2017 September). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clinical Pharmacology & Therapeutics v 102 (3). Available online at https://cpicpgx.org/content/guideline/publication/warfarin/2017/28198005.pdf. Accessed August 2020.
Al-Eitan, L. et. al. (2018 November 27). Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy. Genes (Basel). 2018 Dec; 9(12): 578. Available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316567/. Accessed August 2020.
Ma, Z. et. al. (2019 September 6). Clinical Model for Predicting Warfarin Sensitivity. Sci Rep. 2019 Sep 6;9(1):12856. Available online at https://www.ncbi.nlm.nih.gov/pubmed/31492893. Accessed August 2020.
Chong, K. (2015 November 10, Updated). Warfarin Dosing and VKORC1/CYP2C9. Medscape Genomic Medicine. Available online at https://emedicine.medscape.com/article/1733331-overview. Accessed August 2020.
Sources Used in Previous Reviews
Linnea M. Baudhuin, Ph.D., DABMG, Assistant Professor of Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Shah, S. and Voora, D. (Updated 2010 April 8). Warfarin Dosing and VKORC1/CYP2C9. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/1733331-overview. Accessed May 2011.
Epstein, R. et. al. (2010 March 30). Warfarin Genotyping Reduces Hospitalization Rates Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study). J Am Coll Cardiol, 2010; 55:2804-2812 [On-line information]. Available online at http://content.onlinejacc.org/cgi/content/full/j.jacc.2010.03.009v1. Accessed May 2011.
Moyer, T. (2009 December). Warfarin Sensitivity Genotyping: A Review of the Literature and Summary of Patient Experience. Mayo Clinic Proceedings v 84 (12) 1079-1094 [On-line information]. Available online at http://www.mayoclinicproceedings.com/content/84/12/1079.full. Accessed May 2011.
Mehra, M. (2010 March 16). MM-WES: Genetic testing for warfarin sensitivity linked with reduction in hospitalizations By American College of Cardiology 59th Annual Scientific Sessions. Cardiologytoday [On-line information]. Available online at http://www.cardiologytoday.com/view.aspx?rID=62016. Accessed May 2011.
Bell, J. (2008 October). Experts Debate Pharmacogenetic Testing for Warfarin Sensitivity. Tests Could Enable Better Dosing, But Some Question the Data. AACC 2008 Annual Meeting Highlights, Clinical Laboratory News v 34 (10) [On-line information]. Available online at https://www.aacc.org/publications/cln/2008/october/Pages/am08_highlights1.aspx. Accessed May 2011.
(© 1995–2011). Mayo Medical Laboratories Unit Code 60529: Warfarin Sensitivity Genotype by Sequence Analysis, Blood [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/60529. Accessed May 2011.
Check, W. (2009 January). PGx tests for warfarin dosing—how soon? CAP Today [On-line information]. Available online through http://www.cap.org. Accessed May 2011.
Karp, J. (2010 March 1). SNP Testing for Warfarin Sensitivity. College of American Pathologists NewsPath [On-line information]. Available online through http://www.cap.org. Accessed May 2011.
Krautscheid, Patti et. al. (Updated 2010 June). Warfarin Sensitivity. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/WarfarinSensitivity.html?client_ID=LTD. Accessed May 2011.
Verhoef; T. et. al. (2010 September 17). Clinical and Economic Consequences of Pharmacogenetic-guided Dosing of Warfarin. Medscape Today from Expert Rev Pharmacoeconomics Outcomes Res. 2010;10(4):375-378. [On-line information]. Available online at http://www.medscape.com/viewarticle/727897. Accessed May 2011.
Nainggolan, L. (2009 February 19). Prediction of Initial Dose of Warfarin Aided by Genetic Testing. Medscape News Today from Heartwire [On-line information]. Available online at http://www.medscape.com/viewarticle/588489. Accessed May 2011.
(© 1994-2011). Warfarin (Rx) - Coumadin, Jantoven. Medscape Reference [On-line information]. Available online at http://reference.medscape.com/drug/coumadin-jantoven-warfarin-342182. Accessed May 2011.
(Updated 2011 May 13) Frequently Asked Questions About Pharmacogenomics. National Human Genome Research Institute [On-line information]. Available online at http://www.genome.gov/27530645. Accessed May 2011.
Carlson, E. (2009 February 25). Web Exclusives: Genetics, Math Gives Blood. National Institute of General Medical Sciences [On-line information]. Available online at http://publications.nigms.nih.gov/computinglife/mathblood.htm. Accessed May 2011.
Osinbawale O, et al. An algorithm for managing warfarin resistance. Cleveland Clinic Journal of Medicine December 2009 vol. 76 12 724-730. Available online at http://www.ccjm.org/content/76/12/724.full. Accessed October 2011.
Bussey H, et al. Genetic Testing for Warfarin (Coumadin) Dosing? - Not Yet Ready for Prime Time. July, 2007 from Clot Care Online Resource. Available online at http://www.clotcare.com/warfaringenetictesting.aspx. Accessed October 2011.
Sconce E, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. October 1, 2005 vol. 106 no. 7 2329-2333. Available online at http://bloodjournal.hematologylibrary.org/content/106/7/2329.full. Accessed October 2011.
Chong, K. (2013 November 11, Updated). Warfarin Dosing and VKORC1/CYP2C9. Medscape Drugs and Diseases Available online at http://emedicine.medscape.com/article/1733331-overview. Accessed 03/21/15.
(2013 November 19). Genetic data does not improve anticoagulation control with warfarin. National Heart Lung and Blood Institute Press Release Available online at http://www.nhlbi.nih.gov/news/press-releases/2013/genetic-data-does-not-improve-anticoagulation-control-with-warfarin. Accessed 03/21/15.
(2013 November 19). Genetic testing could improve warfarin dosing. American Heart Association Late-Breaking Clinical Trial Report LBCT 5/Abstract: 19658 (Hall E). American Heart Association. Available online at http://newsroom.heart.org/news/genetic-testing-could-improve-warfarin-dosing. Accessed 03/21/15.
Heikal, N. et. al. (2014 June, Updated). Warfarin Sensitivity. ARUP Consult. Available online at http://www.arupconsult.com/Topics/WarfarinSensitivity.html?client_ID=LTD. Accessed 03/21/15.
(2014 May).Warfarin Sensitivity (CYP2C9 and VKORC1) 3 Mutations. ARUP Laboratories. Available online at http://ltd.aruplab.com/Tests/Pdf/197. Accessed 03/21/15.
Hamberg, A. and Wadelius, M. (2014). Pharmacogenetics-Based Warfarin Dosing in Children. Medscape News and Perspective from Pharmacogenomics. 2014;15(3):361-374. Available online at http://www.medscape.com/viewarticle/821224. Accessed 03/21/15.